Eesti - eesti - Ravimiamet

emergent operations ireland limited - naloksoon - ninasprei, lahus üheannuselises konteineris - 3,6mg 0.1ml 0.1ml 2tk

Eesti - eesti - Ravimiamet

emergent operations ireland limited - naloksoon - ninasprei, lahus üheannuselises konteineris - 1,8mg 0.1ml 0.1ml 2tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - rivaroksabaan - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombootilised ained - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Euroopa Liit - eesti - EMA (European Medicines Agency)

tesaro bio netherlands b.v. - rolapitant - vomiting; nausea; cancer - antiemeetikumid ja antinauseants, - täiskasvanutel kõrge ja mõõduka emetogeense vähivastase kemoteraapiaga seotud hilinenud iivelduse ja oksendamise ennetamine. varuby on esitatud osana kombineeritud ravi.

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - ibandroonhape - õhukese polümeerikattega tablett - 50mg 84tk; 50mg 210tk; 50mg 126tk; 50mg 1tk; 50mg 100tk; 50mg 30tk; 50mg 7tk; 50mg 90tk; 50mg 60tk; 50mg 50tk; 50mg 56tk; 50mg 20tk; 50mg 10tk; 50mg 3tk

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - omeprasool - gastroresistentne kõvakapsel - 10mg 56tk; 10mg 30tk; 10mg 100tk; 10mg 60tk; 10mg 280tk; 10mg 28tk; 10mg 15tk; 10mg 14tk; 10mg 50tk

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - metoprolool - toimeainet prolongeeritult vabastav tablett - 200mg 50tk; 200mg 30tk; 200mg 60tk; 200mg 28tk; 200mg 56tk; 200mg 98tk; 200mg 20tk; 200mg 100tk; 200mg 14tk

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - metoprolool - toimeainet prolongeeritult vabastav tablett - 100mg 10tk; 100mg 20tk; 100mg 98tk; 100mg 28tk; 100mg 50tk; 100mg 60tk; 100mg 56tk; 100mg 30tk; 100mg 14tk; 100mg 100tk

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - ibandroonhape - õhukese polümeerikattega tablett - 150mg 3tk; 150mg 1tk; 150mg 30tk; 150mg 7tk; 150mg 21tk; 150mg 14tk; 150mg 10tk; 150mg 20tk; 150mg 28tk

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - metoprolool - toimeainet prolongeeritult vabastav tablett - 25mg 28tk; 25mg 50tk; 25mg 60tk; 25mg 98tk; 25mg 30tk; 25mg 14tk; 25mg 10tk; 25mg 20tk; 25mg 56tk